[Pathogenesis and therapeutic advances of peripheral T-cell lymphoma]

According to the recently revised WHO classification, peripheral T-cell lymphomas (PTCL) can be classified into up to 30 subtypes. Because the majority of these subtypes were rare cancers, their pathophysiology was not well understood. However, technological advancements including multi-omics approaches such as genomic and gene expression analyses have made significant progress in understanding the pathophysiology of PTCL. Based on the results of these basic studies, the classification of T-cell lymphomas has been changed. Furthermore, new markers discovered through genomic analysis and gene expression analysis are being incorporated into the diagnostic processes of PTCL. Furthermore, multiple new drugs were approved to treat patients of PTCL. Clinical trials are also being carried out as first-line treatments to test the efficacy to combine these new drugs with conventional treatments.